Clinical Trials Logo

Hidradenitis clinical trials

View clinical trials related to Hidradenitis.

Filter by:

NCT ID: NCT04194541 Completed - Clinical trials for Hidradenitis Suppurativa

Wound Dressings for Hidradenitis Suppurativa

Start date: January 28, 2020
Phase: N/A
Study type: Interventional

The primary purpose of this research is to determine how the types of wound dressings affect quality of life for people with Hidradenitis Suppurativa (HS).

NCT ID: NCT04092452 Completed - Acne Inversa Clinical Trials

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Start date: December 2, 2019
Phase: Phase 2
Study type: Interventional

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

NCT ID: NCT04061395 Completed - Clinical trials for Hidradenitis Suppurativa

Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.

HiGUS
Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

This is a multicenter open-label mode of action study. Twenty patients with moderate to severe hidradenitis suppurativa will be treated with guselkumab 200 mg Q4W subcutaneously. Main objectie is to investigate changes in inflammatory pathways induced by IL-23p19 blockade with guselkumab, in HS lesional skin. The total duration of the treatment period per subject is 16 weeks.

NCT ID: NCT04019041 Completed - Clinical trials for Hidradenitis Suppurativa

A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

Start date: September 16, 2019
Phase: Phase 2
Study type: Interventional

This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other week injections of bermekimab or placebo, and 1/3 will receive weekly injections of placebo.

NCT ID: NCT04018599 Completed - Clinical trials for Rheumatoid Arthritis

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Start date: July 15, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection of 40 mg.

NCT ID: NCT03972280 Completed - Clinical trials for Hidradenitis Suppurativa

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Start date: July 4, 2019
Phase: Phase 1
Study type: Interventional

Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. CSL324 is a novel, recombinant therapy that may treat diseases caused by increased numbers of neutrophils at sites of inflammation.

NCT ID: NCT03960268 Completed - Clinical trials for Hidradenitis Suppurativa

Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Start date: May 28, 2019
Phase: Early Phase 1
Study type: Interventional

Phase 0 Study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.

NCT ID: NCT03926169 Completed - Clinical trials for Hidradenitis Suppurativa

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

DETERMINED 1
Start date: June 3, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult participants diagnosed for at least one year before the Baseline visit.

NCT ID: NCT03894956 Completed - Clinical trials for Hidradenitis Suppurativa (HS)

Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa

Start date: May 2, 2019
Phase:
Study type: Observational

The objective of this study is to evaluate the long-term safety and effectiveness of Humira in patients with Hidradenitis Suppurativa (HS) in real-world clinical practice in Japan.

NCT ID: NCT03852472 Completed - Clinical trials for Hidradenitis Suppurativa

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Start date: December 21, 2018
Phase: Phase 2
Study type: Interventional

Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa